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Primary small-cell cancer of the esophagus 
Primary small-cell cancer of the esophagus i a rare tumor that disseminates arly with a uniformly 
poor prognosis if untreated. Sixteen patients with malignant dysphagia referred to the Thoracic 
Surgical Unit, City Hospital, Edinburgh, within a 10-year period had a diagnosis of primary 
small-cell cancer of the esophagus. Seven patients underwent subtotal esophagectomy or esophago- 
gastrectomy, either alone or with adjuvant chemotherapy or radiotherapy, with a mean survival of 
20 months (standard deviation 35.4 months, range 2 weeks to 96 months). The remaining nine 
patients had disseminated disease when they were first seen and were treated symptomatically b
intubation alone (1 patient), intubation and palliative chemotherapy or radiotherapy (3 patients), 
palliative chemotherapy (2 patients), palliative radiotherapy (1 patient), or no therapy (2 patients), 
with a mean survival of 4.8 months (standard eviation 2.6 months, range 2 to 9 months). Patients 
seen with this aggressive tumor should be assessed urgently for evidence of metastatic spread and 
then offered resection in combination with chemotherapy if they are otherwise fit for operation. This 
treatment regimen has given us one long-term survivor (96 months) who, we believe, is the only 
patient o have been cured of this condition. Patients seen with disseminated disease should have 
symptomatic treatment of the dysphagia combined with palliative chemotherapy. (J THORAC 
CARDIOVASC SURG 1995;109:284-88) 
S. R. Craig, FRCS, a F. A. Carey, MRCPath, b W. S. Walker, FRCS, a and 
E. W. J. Cameron, FRCS, a Edinburgh, Great Britain 
P: imary  small-cell cancer of the esophagus, first 
reported by McKeown 1 in 1952, is a rare tumor, 
similar to small-cell cancer of the lung, character- 
ized by early dissemination and death if untreated. 2 
Esophageal small-cell carcinoma is identical mor- 
phologically to its more common bronchial counter- 
part, consisting of round to spindle-shaped cells with 
scanty cytoplasm, granular nuclei, inconspicuous 
nucleoli, and ultrastructural nd immunohistochem- 
ical evidence of neuroendocrine differentiation. The 
cells may be argyrophil positive with neurosecretory 
granules seen on electron microscopy. 3 Immuno- 
histologically these cells are immunoreactive with 
low-molecular-weight cytokeratins and epithelial 
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membrane antigen, which is similar to the immuno- 
reactivity of bronchogenic small-cell cancer. 4 Neo- 
plasms of the small-cell type have been recognized 
in a variety of extrapulmonary sites including, most 
frequently, the esophagus. 5 The management of 
primary small-cell cancer of the esophagus remains 
controversial with groups reporting treatment based 
on operation alone, 6 local radiotherapy, 7 chemo- 
therapy alone, 3' s, 9 or operation with adjuvant her- 
apy. 1° Overall survival remains poor at a mean of 5.1 
months, with the best rate of survival in patients 
undergoing operation with adjuvant chemotherapy. 2 
This report describes the clinical and pathologic 
features of 16 patients een at our thoracic surgical 
unit with primary small-cell cancer of the esophagus 
and outlines a management s rategy based on the 
available literature, which at present stands at fewer 
than 200 cases reported worldwide. 
Patients and methods 
Patients with a diagnosis of small-cell cancer of the 
esophagus were identified from clinical and pathologic 
records from a 10-year period. The clinical, radiographic, 
and pathologic findings were reviewed and all patients in 
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Table I. Summary of patients who underwent operation for small-cell carcinoma of esophagus 
Age 
Patient (yr) Sex Operation Survival Recurrence Adjuvant therapy 
1 39 F Subtotal esophagectomy Alive at 96 mo None Chemotherapy 
2 57 F Subtotal esophagectomy Died at 12 mo Pulmonary at 4 mo, Palliative radiother- 
bone at 9 mo apy for bone me- 
tastases 
3 63 M Esophagogastrectomy Died at 34 mo Anastomotic at 24 Laser therapy 
mo 
4 64 F Esophagogastrectomy, Died at 5 wk Rapid deteriora- None 
splenectomy, partial pan- tion, no postmor- 
createctomy tem study 
5 62 F Esophagogastrectomy Alive at 6 mo None Radiotherapy to me- 
diastinum 
6 48 F Subtotal esophagectomy Died at 2 wk N/A None 
7 55 F Subtotal esophagectomy Died at 3 mo N/A None 
Chemotherapy consisted ofmethotrexate, cyclophosphamide, etoposide. 
whom esophageal invasion by a primary bronchial small- 
cell carcinoma could not be ruled out were excluded from 
the study. A total of 16 patients identified from the 
records were considered to have a primary esophageal 
small-cell carcinoma. 
The records were examined and the presenting symp- 
toms, method of tumor diagnosis, staging procedures 
done, therapy, pathologic findings, and clinical outcome 
recorded. Histologic sections were reviewed to confirm 
the diagnosis of small-cell carcinoma. Features of associ- 
ated dysplasia/carcinoma in situ, Barrett's esophagus, 
mixed patterns of histologic differentiation, and lymph 
node metastases were specifically sought. Immunohisto- 
chemistry testing for epithelial and lymphoid markers was 
done when lymphoma had been included in the differen- 
tial diagnosis. 
Results 
Sixteen patients with primary small-cell cancer of 
the esophagus were identified within a 10-year pe- 
riod during which more than 600 esophagogastrec- 
tomies because of esophageal or proximal gastric 
cancer were done. There were 11 women and 6 men 
with an age range of 39 to 72 years (mean 60 years). 
Seven of these patients had been treated primarily 
by resection and nine had been given palliative 
treatment because of dissemination of the primary 
tumor at the time of presentation. All patients 
reported ysphagia nd weight loss; in addition one 
had hematemesis and melena and two were hoarse 
because of vocal cord paralysis as a result of involve- 
ment of the left recurrent laryngeal nerve. 
Surgical group. Seven patients had the primary 
small-cell cancer of the esophagus resected on the 
grounds that the preoperative work-up had excluded 
distant metastatic disease. A summary of the details 
of these patients is given in Table I. All patients had 
endoscopic and contrast examinations of the esoph- 
agus and no evidence of a bronchogenic small-cell 
primary tumor on bronchoscopy, chest radiograph, 
or thoracic omputed tomographic (CT) scan. Liver 
ultrasonography was done before resection in all 
patients to exclude liver metastases. Calcium, phos- 
phate, and alkaline phosphatase l vels were mea- 
sured in an attempt o exclude occult bone metas- 
tases. Any history of bone pain was investigated by 
radiograph and isotopic bone scan. Pulmonary func- 
tion tests were done along with a full noninvasive 
assessment of cardiac function before thoracolapa- 
rotomy. 
A preliminary laparotomy was done in all cases to 
exclude xtranodal spread. Four patients underwent 
a subtotal esophagectomy, two an esophagogastrec- 
tomy, and one an esophagogastrectomy combined 
with splenectomy and partial pancreatectomy. After 
resection an esophagogastrostomy was fashioned 
with a circular stapler (ILS stapler, Ethicon Ltd., 
Edinburgh, United Kingdom) or interrupted silk 
sutures (Mersilk, Ethicon Ltd.). A barium contrast 
examination was done on postoperative day 5 to 
check the anastomosis. All patients were closely 
monitored in the outpatient department after dis- 
charge from the hospital. 
All patients who underwent esophageal resection 
had histologically confirmed small-cell cancer of the 
esophagus (Table II). The surgical resection speci- 
mens showed mixed histologic types in four out of 
the seven cases. In three of these the appearances 
were of mixed squamous and small-cell carcinoma 
and one case showed mixed small-cell carcinoma 
and adenocarcinoma. Three of the seven resected 
specimens howed foci of squamous carcinoma in 
situ, and this change was extensive in one case. 
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Table II. Pathologic findings in patients who 
underwent resection for primary esophageal small- 
cell cancer 
Lymph node Resection 
Patient Histologic type status margins 
1 Small-cell carcinoma Metastases in two Clear 
lymph nodes 
2 Small-cell carcinoma Metastases in Clear 
and adenocarci- multiple nodes 
noma 
3 Small-cell carcinoma Metastasis in sin- Clear 
gle lymph node 
4 Small-cell carcinoma Lymph nodes Clear 
normal 
5 Small-cell carcinoma Metastases in two Clear 
and squamous lymph nodes 
carcinoma 
Small-cell carcinoma 
and squamous 
carcinoma 
7 Small-cell carcinoma Metastases in Clear 
and squamous multiple nodes 
carcinoma 
6 Metastases in Clear 
multiple nodes 
Barrett's metaplasia was not detected in any of the 
specimens. In keeping with early dissemination all 
but one patient had evidence of local nodal metas- 
tases. The patient with no evidence of nodal meta- 
static disease did have microscopic invasion of the 
perigastric fat. 
In the postoperative period ehylothorax and re- 
spiratory failure developed in one patient who had 
had a subtotal esophagectomy, which required a 
prolonged period of ventilation and parenteral nu- 
trition. Other perioperative complications included 
a chest infection (1 patient) and atrial fibrillation (1 
patient). One patient died at 14 days (operative 
mortality rate 14%) of a pulmonary embolus. 
The patient with perigastric fat invasion died of 
rapid progression of the disease and was too frail to 
undergo any form of palliative therapy, as was 
another patient who died at 3 months. This patient, 
it is presumed, must have had undiagnosed meta- 
static disease at the time of presentation. The other 
four patients fared better with a mean survival of 37 
months (standard eviation 41.1 months, range 6 to 
96 months). Two patients are alive, one at 96 
months who underwent adjuvant chemotherapy and 
one at 6 months with no evidence of recurrence who 
received mediastinal radiotherapy for lymphatic me- 
tastases. The chemotherapy consisted of four 
courses of methotrexate, cyclophosphamide, and 
etoposide. The other two patients died at 12 and 34 
months, respectively. The patient who died at 12 
months had pulmonary and then bone metastases 
that developed shortly after a prolonged in-patient 
hospital stay because of a chylothorax and respira- 
tory failure, which necessitated a period of ventila- 
tor support. She received palliative radiotherapy to 
the symptomatic bone metastases. 
The patient who died at 34 months had received 
no adjuvant herapy; however, he remained well 
until an anastomotic recurrence was diagnosed 24 
months after operation despite initially clear resec- 
tion margins. He received laser therapy to the 
anastomotic recurrence, which relieved dysphagia 
until his death 10 months later. 
Palliative group. Nine patients were identified 
with disseminated disease at the time of presenta- 
tion. Small-cell esophageal cancer was diagnosed by 
endoscopic biopsy in all cases. In the biopsy speci- 
mens the tumor consisted of sheets and nests of 
polygonal to spindle-shaped cells with a fine fibro- 
vascular supporting network. Crush artifact was 
common. In two cases immunohistochemical stain- 
ing for cytokeratin showed a characteristic paranu- 
clear "dot" positivity. A further two cases showed 
foci of squamous differentiation. The overlying 
squamous epithelium showed dysplasia in three 
patients and features of carcinoma in situ in one. 
Four patients had cervical ymphadenopathy that 
was subjected to biopsy and confirmed histologically 
to be metastatic small-cell cancer similar in appear- 
ance to the esophageal primary tumor. Two patients 
were hoarse because of involvement of the left 
recurrent laryngeal nerve associated with gross me- 
diastinal lymphadenopathy on thoracic CT scan. 
One patient had liver metastases, one had extensive 
mediastinal and abdominal ymphadenopathy on 
CT scan, and one was too frail to contemplate 
esophageal resection. These patients with dissemi- 
nated disease were treated by intubation alone (1 
patient), intubation and palliative chemotherapy or
radiotherapy (3 patients), palliative chemotherapy 
(2 patients), palliative radiotherapy (1 patient), or 
no therapy (2 patients). All patients were followed 
up in our outpatient department if no adjuvant 
therapy was given or by the oncologists or radiother- 
apists if they did receive adjuvant herapy. 
The result of palliative treatment for the nine 
patients with disseminated disease at the time of 
presentation is summarized in Table III. Four pa- 
tients required intubation of the malignant esopha- 
geal stricture because of severe dysphagia t the 
time of presentation. Six patients were treated with 
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Fig. 1. Histologic section from surgical resection specimen showing mixed squamous cell and small-cell 
carcinoma (hematoxylin and eosin stain, original magnification × 100). 
Table III. Outcome of patients with disseminated disease at presentation 
Patient Age (yr) Sex Reason for nonoperative status Palliation Outcome 
1 64 F 
2 70 F 
3 69 M 
4 69 F 
5 55 M 
6 72 M 
7 65 M 
8 65 F 
9 43 F 
Cervical ymph nodes 
Extensive mediastinal lymphadenopathy 
Cervical ymph nodes 
Liver metastases 
Extensive mediastinal lymphadenopathy 
Extensive para-aortic lymphadenopathy 
Cervical ymph nodes 
Extensive mediastinal lymphadenopathy 
Cervical ymph nodes 
None, rapid eterioration; flail Died 2 mo 
None, rapid deterioration; frail Died 2 mo 
Chemotherapy Died 7 mo 
Palliative radiotherapy Died 3 rno 
Intubation, radiotherapy, che- Died 7 mo 
motherapy 
Intubation Died 3 mo 
Intubation, chemotherapy Died 7 mo 
Intubation Died 3 mo 
Chemotherapy Died 9 mo 
Chemotherapy consisted of methotrexate, cyclophosphamide, etoposide. 
palliative chemotherapy or radiotherapy with a 
mean survival of 6 months (1 standard error of 
mean). The three remaining patients who were unfit 
for any form of palliative therapy died at a mean 
time of 2 months after diagnosis. 
Discussion 
Over the past decade or so, small-cell carcinoma 
has become increasingly recognized as an unusual 
primary neoplasm of the esophagus. Small-cell car- 
cinoma was initially thought o arise from argyro- 
philic Kulchitsky cells, which are found in both 
bronchial and esophageal mucosa. 11 These cells 
have the ability to synthesize and store amines and 
to decarboxylate some amino acids: a feat that gave 
rise to the term APUD (amine precursor uptake, 
decarboxylation) cells, a2 It would now appear that 
small-cell cancer is of endodermal origin derived 
from a pluripotential basal epithelial cell, similar to 
the proposed histogenesis of bronchogenic small- 
cell carcinoma, which explains the coexistence of 
small-cell, squamous, and glandular elements in the 
same lesion. 13 Approximately 35% of primary small- 
cell cancers of the esophagus how this multiple 
differentiation, a4 Our finding of a high incidence of 
histologic heterogenicity (Fig. 1) in surgically re- 
sected esophageal small-cell cancers (higher, in fact, 
than that of small-cell lung cancers) and of an 
association with squamous carcinoma in situ 
strongly supports this unified hypothesis. 
Primary small-cell carcinoma of the esophagus 
has previously been labeled as an argyrophilic ell 
carcinoma (apudoma), 6 as well as an oat cell, 15 
16 17 anaplastic, neuroendocrine, or small-cell epider- 
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moid carcinoma, 18 reflecting the previously uncer- 
tain histogenesis of this tumor. 
Small-cell cancer of the esophagus shares immu- 
nohistochemical, histochemical, and histologic sim- 
ilarities with small-cell cancer of the bronchus, 
which suggests that they have a common deriva- 
tion. 14 They are both aggressive cancers character- 
ized by early dissemination, which reduces the num- 
ber of operable cancers at the time of diagnosis, 
though they do both have a significant response rate 
to appropriate chemotherapy. 3' 8,19 Those patients 
seen with esophageal small-cell cancer should be 
assessed with regards to ensuring that the tumor is a 
primary esophageal tumor and the extent of spread 
should be determined. Patients with disseminated 
disease should be offered palliative therapy associ- 
ated with esophageal intubation if required. Al- 
though numbers are small it would appear that 
palliative chemotherapy offers longer survival than 
palliative radiotherapy}' 7, 8, 9 
Patients with apparent operable disease should be 
offered resection in combination with adjuvant che- 
motherapy. It is to be expected that adjacent lymph 
nodes will be involved by metastatic deposits though 
this in itself does not rule out a prolonged period of 
survival, as this paper has shown. Other authors 
have suggested additional mediastinal and cranial 
irradiation if these glands are involved on the basis 
of existing treatment protocols for bronchogenic 
small-cell cancer} 
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